期刊
CALCIFIED TISSUE INTERNATIONAL
卷 90, 期 5, 页码 404-410出版社
SPRINGER
DOI: 10.1007/s00223-012-9584-7
关键词
AMP-activated protein kinase; Bone resorption; (-)-Epigallocathechin-3-gallate; Osteoclast
资金
- Korea Health Technology RD Project
- Ministry of Health & Welfare, Republic of Korea [A110536]
- Asan Institute for Life Sciences (Seoul, Korea) [2011-523]
Previously, we showed that AMP-activated protein kinase (AMPK) negatively regulates receptor activator of nuclear factor-kappa B ligand-induced osteoclast formation in vitro. The present study investigated the effect of (-)-epigallocathechin-3-gallate (EGCG), an AMPK activator, on ovariectomy (OVX)-induced bone loss in mice. Female mice subjected to OVX were administered EGCG for 8 weeks. We measured total-body bone mineral density (BMD) before and after the operation at an interval of 4 weeks. We performed micro-computed tomography (micro-CT) of the tibia and bone histomorphometric examination of the femur. Western blot analysis was additionally performed, to detect levels of the phosphorylated and total forms of AMPK-alpha in calvarial extracts. EGCG prevented OVX-induced body weight gain. The OVX control did not show a significant increase in BMD values at baseline and after treatment, unlike the sham control. EGCG attenuated OVX-induced bone loss. Micro-CT experiments revealed that EGCG induced a significant increase in trabecular bone volume and trabecular number and a decrease in trabecular spacing compared to the OVX control. Histomorphometric analyses further showed that EGCG suppressed osteoclast surface and number. Phosphorylated AMPK expression was significantly elevated in bone following EGCG treatment. Our findings collectively indicate that EGCG decreases OVX-induced bone loss via inhibition of osteoclasts.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据